Skip to main content
OpenTrials
Completed

NCT Number: NCT01237860

Evaluation of the Safety and Performance of the NESS L300 Plus System

The study is designed to evaluate the safety and efficacy of using the L300 Plus as a neuroprosthesis device for walking in patients following an UMN injury or disease. The clinical study is proposed to determine the anticipated adverse event rate and treatment outcomes at the conclusion of the study.

Completed

Looking for future studies?

Notify Me

Key information

About this study

This is a prospective, one-center, single group, repeated measures, non inferiority study. Forty-five (45) subjects suffering from foot drop and thigh muscles weakness due to upper motor neuron injury or disease will be evaluated for this study. Each subject will be in the study for six weeks. Clinical benefits will be measured through an assessment of the gait performance. In particular it will test the hypothesis that the NESS L300 Plus System which involves foot drop correction with thigh muscles activation, may achieve walking enhancements not inferior to those gained from using a system that only corrects foot drop (i.e. NESS L300).

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Upper motor neuron lesion
  • Thigh muscle weakness - hamstrings or quadriceps strength of less than 4/5 according to manual muscle testing
  • Foot drop - toe drag during walking
  • Lower limb spasticity - 0-4 according to the modified Ashworth scale
  • Responsible mental state, able to follow multiple step directions
  • Between 18 and 80 years old
  • Available for participation in the study
  • Able to understand and sign the informed consent form
  • Able to walk independently or with an assistance device (e.g. cane, walker etc.) / spot guarding for at least 10 meters
  • Sufficient response to electrical stimulation (visible muscle contractions in a seated or prone position of each designated muscle separately)

Exclusion criteria

  • Subjects with a demand-type cardiac pacemaker, defibrillator or any electrical or metallic implant
  • Cancerous lesion of lower limb, present or suspected
  • Medical condition that prevents participation or would likely lead to inability to comply with the protocol [e.g.: congestive heart failure, patient receiving chemotherapy, uncontrolled epilepsy, etc]
  • Severe cognitive impairment (MMSE<21)
  • Severe neglect (Star cancellation test<30)
  • Skin lesion at the site of the stimulation electrodes
  • Change in bone-joint structures of the lower limb, such as contractures or deformations; fracture or dislocation, which would be adversely affected by motion from the stimulation
  • Pregnancy
  • Diagnosis of major depression or psychotic disorder
  • Participation in another investigation that may directly or indirectly affect the study results
  • Unable to tolerate electrical stimulation

Treatment and study plan

NESS L300 Plus System

Device

The patients will receive the device for daily use of six (6) weeks.

Other names: NESS L300, L300, L300 Plus

Primary outcomes

  1. Occurence of anticipated and unanticipated adverse events

    Time frame: Throughout the 6 weeks of the study

    The occurence of anticipated and unanticipated events will be documented at each scheduled evaluation. In addition, subjects will be instructed to report adverse events 24 hours per day during the study period.

  2. Subject feedback regarding the safety of using the device

    Time frame: Week 6

    Patient feedback regarding the safety of using the device as reported during the study sessions and the completion of a satisfaction questionnaire will also be used to assess the system's safety.

Secondary outcomes

  1. Temporal Gait Parameters of the 2 Minute Walk Test

    Time frame: Week 1 and Week 6

    This outcome measure includes the following: gait velocity, gait asymmetry, single limb support (percentage of the singe stance phase).

  2. 10 Meter Obstacle Course Walking Velocity

    Time frame: Week 1 and Week 6

    To imitate daily life situations, average gait speed will be also determine by measuring the time to walk 10m over an obstacle course, using the protocol in the Emory Functional Ambulation Profile.

Sponsors and collaborators

Lead sponsor

Bioness Inc

Industry

Collaborators

  • Bioness Neuromodulation

Registry information

Acronym: L300Plus

Important dates

Study start
2010
Primary completion
2011
Study completion
2011
First posted
Nov 10, 2010
Registry last updated
Nov 16, 2011

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.